Harnessing Substituted 4-Chlorothieno[2,3-<i>b</i>]pyridine as a New Cap for Potent and Selective Antiproliferative HDAC Inhibitors. [PDF]
Badran MM +13 more
europepmc +1 more source
HDAC inhibitors restore osteoimmune balance and bone regeneration via selective MAPK modulation in inflammatory bone disease. [PDF]
Kim H, Kang L, Park SY.
europepmc +1 more source
HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma. [PDF]
Shen C +7 more
europepmc +1 more source
Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential. [PDF]
Raucci A, Zwergel C, Valente S, Mai A.
europepmc +1 more source
Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulation. [PDF]
Tian J +5 more
europepmc +1 more source
Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors. [PDF]
Carlos JAEG +7 more
europepmc +1 more source
A short overview of dual targeting HDAC inhibitors. [PDF]
Liu WB, Song J, Zhang SY.
europepmc +1 more source
Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high-grade IDH mutant gliomas. [PDF]
Sears TK +7 more
europepmc +1 more source
HDAC Inhibitors Enhance the Chemosensitivity of Osteosarcoma Cells to Etoposide by Suppressing the Hippo/YAP Signaling Pathway. [PDF]
Cao Z +8 more
europepmc +1 more source
Dose-dependent dual effects of HDAC inhibitors on glial inflammatory response. [PDF]
Mancino S +6 more
europepmc +1 more source

